The US-based Abraxis BioSciences’ anti-cancer drug Abraxane has been denied patent by the Indian Patent Office (IPO) on grounds that the new drug does not constitute a fresh innovation.
Citing Section 3 (d) in the Indian Patents Act, which prohibits grant of patents to new forms of known substances unless it results in enhanced efficacy over the known substance, the IPO struck down the patent application June 18.
The patent office based its decision on the Supreme Court’s ruling in the landmark Glivec case. Swiss drugmaker, Novarti, had sought patent protection for Glivec, a cancer drug. However, the application was rejected by the Supreme Court of India in April 2013, citing section 3 (d) in the Indian Patents Act.
Background
The IPO had first quashed the patent application filed by Abraxis in 2009. Subsequently, the US-based pharmaceutical company lodged an appeal against the order with the Intellectual Property Appellate Board (IPAB), which referred the case back to the IPO for fresh consideration in January 2014. The application was rejected for a second time on June 18.
The rejection of the patent application is not the only problem that has clouded the fate of Abraxane in India. Even before Abraxis received patent protection from the US, Indian pharma company Natco had challenged its patent application on the basis that it had already launched an indigenous version of the drug called Albupax in 2008. Albupax was the first nanotech-based cancer drug developed indigenously, but has evoked safety concerns. Natco is yet to launch the drug again.
Winners and Losers
The rejection of the patent to the US-based company will encourage the Indian pharmaceutical companies in making generic versions of the drug available to India and other developing countries at a fraction of the original cost. The Indian pharmaceutical industry, worth 15 billion USD a year, is already mired in a controversy over the production and export of cheaper varieties of drugs that have been reportedly pioneered by the western countries. Abraxis’ loss will deal another blow to the western pharmaceutical companies looking to improve sales in India and elsewhere, while marking a victory for local generic drug-makers.
Author Profile
- India Writes Network (www.indiawrites.org) is an emerging think tank and a media-publishing company focused on international affairs & the India Story. Centre for Global India Insights is the research arm of India Writes Network. To subscribe to India and the World, write to editor@indiawrites.org. A venture of TGII Media Private Limited, a leading media, publishing and consultancy company, IWN has carved a niche for balanced and exhaustive reporting and analysis of international affairs. Eminent personalities, politicians, diplomats, authors, strategy gurus and news-makers have contributed to India Writes Network, as also “India and the World,” a magazine focused on global affairs.
Latest entries
India and the WorldDecember 24, 2024Bridging the Gulf: Modi’s visit transforms India-Kuwait relations- DiplomacyDecember 14, 2024India, Iran and Armenia Advance Connectivity Push with Trilateral Talks in New Delhi
- DiplomacyDecember 13, 2024Brazil’s G20 Presidency will focus on tangible results on UNSC reforms, climate action
- DiplomacyDecember 6, 2024India and Vietnam Strengthen Security Ties at 3rd Deputy Ministerial-Level Dialogue
